Stock fact sheet · data as of
Anbio Biotechnology Class A Ordinary Shares (NNNN): fair value, margin of safety and Wheel Score
Healthcare · Medical - Instruments & Supplies · Germany · Value
Is NNNN undervalued?
NNNN has a margin of safety of 39%: the stock closed at 3.30 on 16 Oct 2026 against a GLS average fair value of 5.39. 3 of the 6 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
The 6 models disagree widely: DCF gives 0.7059 while GLS Growth gives 11.84. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files NNNN under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for NNNN
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 0.7059 | -79% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 1.73 | -48% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 11.06 | +235% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 4.84 | +47% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 11.84 | +259% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 2.15 | -35% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.6870 | -79% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - NNNN passes 5 of the nine Piotroski tests, which falls one point short of the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is 6.8 out of 10: a ten-year record that is consistent in some of the metrics the score tracks (revenue, earnings, margins, cash flow, returns on capital) and patchy in others.
Returns on capital are high - ROIC 21.2%, ROE 21.2%, ROA 21.2% - with debt at 0.00 times equity and negative free cash flow.
Anbio Biotechnology Class A Ordinary Shares pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | 21.2% |
|---|---|---|---|
| GLS Moat | 6.8 / 10 | ROE | 21.2% |
| Debt / equity | 0.00 | ROA | 21.2% |
| Free-cash-flow yield | 0.0% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 39: No options
NNNN has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 70k shares a day on a market cap of $145M, with a beta of 5.26 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 0 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 39% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 10 / 15 | moat 6.8/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 0 / 20 | 70k shares/day, $145M cap, beta 5.26 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for NNNN in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Medical - Instruments & Supplies
The 12 companies below are the closest to Anbio Biotechnology Class A Ordinary Shares by market cap within the Medical - Instruments & Supplies industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| KRMD KORU Medical Systems, Inc. | 3.03 | 0.2707 | -1019% | 28Weak | $139M |
| PDEX Pro-Dex, Inc. | 59.82 | 87.22 | +31% | 39No options | $193M |
| STXS Stereotaxis, Inc. | 1.05 | - | - | 36Weak | $105M |
| UTMD Utah Medical Products, Inc. | 74.79 | 47.66 | -57% | 29No options | $237M |
| OSUR OraSure Technologies, Inc. | 3.81 | 0.4612 | -726% | 38Weak | $263M |
| SMTI Sanara MedTech Inc. | 35.12 | 62.66 | +44% | 39No options | $323M |
| DXR Daxor Corporation | 10.20 | 42.03 | +76% | 39No options | $60M |
| EMBC Embecta Corp. | 6.45 | 35.51 | +82% | 74Good | $365M |
| POCI Precision Optics Corporation, Inc. | 4.41 | - | - | 31No options | $48M |
| ANGO AngioDynamics, Inc. | 11.58 | 1.22 | -853% | 45Weak | $487M |
| NEPH Nephros, Inc. | 3.51 | 5.34 | +34% | 39No options | $38M |
| HBIO Harvard Bioscience, Inc. | 8.31 | - | - | 32No options | $38M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about NNNN
Is NNNN undervalued right now?
By the GLS models, yes: at 3.30 the stock is 39% below the average fair value of 5.39 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of NNNN and what does it mean?
NNNN has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for NNNN?
5.39 per share as of 16 Oct 2026 - the simple average of the 6 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Anbio Biotechnology Class A Ordinary Shares report earnings next?
No upcoming earnings date is recorded for NNNN in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does NNNN have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on NNNN, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.